Tectonic Therapeutic Announces Q2 2025 Financial Results, Initiates TX45 PH-ILD Trial in 2026.

• Tectonic Therapeutic announces Q2 2025 financial results • TX45 PH-ILD Phase 2 clinical trial to initiate in 2026 • TX45 Phase 1b clinical trial results confirm tolerability and improvements in pulmonary hemodynamics • Part B of TX45 Phase 1b clinical trial completed • TX45's therapeutic breadth to expand to PH-ILD • Tectonic Therapeutic focuses on digital data in financial analysis

Watertown, Mass., July 02, 2025 — Tectonic Therapeutic, Inc. (NASDAQ: TECX) has announced its financial results for the second quarter ended June 30, 2025, alongside significant updates on its clinical trials and business highlights. The company reported a net loss of $20.0 million for the quarter, compared to a net loss of $12.7 million for the same period in 2024. Research and development expenses increased to $17.2 million, up from $7.1 million, primarily due to increased costs related to clinical trials and the development of new therapies.

One of the key highlights from the quarter was the completion of enrollment in Part B of the TX45 Phase 1b clinical trial, which evaluates the drug in subjects with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (PH-HFrEF). The topline results for this trial are expected in early Q4 2025. Additionally, the company announced that it will initiate a Phase 2 clinical trial for TX45 in patients with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD), known as Group 3 PH. This trial is expected to begin in 2026 and will evaluate TX45’s safety and hemodynamic effects in approximately 20 subjects.

The company also reported that it has been added to the Russell 3000® Index as part of FTSE Russell’s annual reconstitution, broadening its exposure to institutional investors and reflecting its growing market capitalization. This inclusion comes after the presentation of complete results from Part A of the TX45 Phase 1b clinical trial at the European Society of Cardiology (ESC) Heart Failure 2025 Congress. These results showed that TX45 demonstrated significant improvements in pulmonary capillary wedge pressure (PCWP) and pulmonary vascular resistance (PVR) in subjects with combined pre- and post-capillary pulmonary hypertension (CpcPH).

Looking ahead, Tectonic anticipates that its current cash and cash equivalents, totaling $287.4 million as of June 30, 2025, will provide a cash runway into Q4 2028. The company expects to continue enrolling in its ongoing TX45 APEX Phase 2 clinical trial, with topline results expected in 2026. Additionally, TX2100, a GPCR antagonist being developed as a potential treatment for Hereditary Hemorrhagic Telangiectasia (HHT), is expected to initiate a Phase 1 clinical trial in healthy volunteers in Q1 2026.

References:
[1] https://www.marketscreener.com/news/tectonic-therapeutic-announces-second-quarter-2025-financial-results-and-recent-business-highlights-ce7c5edcd988f521